FY2027 EPS Estimates for Arvinas Lowered by Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Analysts at Leerink Partnrs cut their FY2027 earnings estimates for shares of Arvinas in a research report issued on Monday, February 3rd. Leerink Partnrs analyst A. Berens now expects that the company will earn $1.08 per share for the year, down from their previous estimate of $1.38. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share.

Several other brokerages also recently weighed in on ARVN. BMO Capital Markets reduced their price target on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Barclays reduced their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a report on Monday. Oppenheimer lowered their price target on Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a report on Wednesday, December 11th. Finally, Guggenheim restated a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $61.45.

Arvinas Stock Performance

Shares of Arvinas stock opened at $19.10 on Thursday. The company has a 50-day simple moving average of $19.75 and a two-hundred day simple moving average of $23.67. The stock has a market capitalization of $1.31 billion, a PE ratio of -4.09 and a beta of 1.88. Arvinas has a 52-week low of $16.61 and a 52-week high of $53.08.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. nVerses Capital LLC bought a new position in Arvinas in the 3rd quarter worth $39,000. Mirae Asset Global Investments Co. Ltd. increased its position in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares in the last quarter. KBC Group NV raised its stake in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares during the period. Quantbot Technologies LP lifted its position in shares of Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after buying an additional 2,601 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in shares of Arvinas by 37.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $164,000 after acquiring an additional 1,798 shares during the period. Hedge funds and other institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.